Evidence map›Paper›PMID 36196452›Full record

ArticleRevista panamericana de salud publica = Pan American journal of public health2022

[Adverse reactions to drugs used for COVID-19 in five Latin American countriesReações adversas a medicamentos utilizados para a COVID-19 em cinco países da América Latina].

Tatiana Orjuela-Rodríguez, Robin Rojas-Cortés, Verónica Vergara, Francisca Aldunate, Giset Jiménez, Ismary Alfonso Orta, Kelly Serrano, Giovanna Jiménez, Diana Marcela Gil González, Diego Gutiérrez and 4 more

Open access · diamondAbstract readEnglish Abstract
In one paragraph

Article in Revista panamericana de salud publica = Pan American journal of public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 4 countries.

Tatiana Orjuela-RodríguezConsultora independiente Bogotá Colombia Consultora independiente, Bogotá, Colombia.
Robin Rojas-CortésOrganización Panamericana de la Salud Washington D.C. Estados Unidos de América Organización Panamericana de la Salud, Washington D.C., Estados Unidos de América.
Verónica VergaraInstituto de Salud Pública Santiago Chile Instituto de Salud Pública, Santiago, Chile.
Francisca AldunateInstituto de Salud Pública Santiago Chile Instituto de Salud Pública, Santiago, Chile.
Giset JiménezCentro Estatal de Medicamentos Equipos y Dispositivos Médicos La Habana Cuba Centro Estatal de Medicamentos, Equipos y Dispositivos Médicos, La Habana, Cuba.
Ismary Alfonso OrtaCentro Estatal de Medicamentos Equipos y Dispositivos Médicos La Habana Cuba Centro Estatal de Medicamentos, Equipos y Dispositivos Médicos, La Habana, Cuba.
Kelly SerranoDirección General de Medicamentos Insumos y Drogas Lima Perú Dirección General de Medicamentos, Insumos y Drogas, Lima, Perú.
Giovanna JiménezDirección General de Medicamentos Insumos y Drogas Lima Perú Dirección General de Medicamentos, Insumos y Drogas, Lima, Perú.
Diana Marcela Gil GonzálezInstituto Nacional de Vigilancia de Medicamentos y Alimentos Bogotá Colombia Instituto Nacional de Vigilancia de Medicamentos y Alimentos, Bogotá, Colombia.
Diego GutiérrezInstituto Nacional de Vigilancia de Medicamentos y Alimentos Bogotá Colombia Instituto Nacional de Vigilancia de Medicamentos y Alimentos, Bogotá, Colombia.
Francisco Bosco CortezDirección Nacional de Medicamentos Santa Tecla El Salvador Dirección Nacional de Medicamentos, Santa Tecla, El Salvador.
José David GonzálezDirección Nacional de Medicamentos Santa Tecla El Salvador Dirección Nacional de Medicamentos, Santa Tecla, El Salvador.
Analía PorrásOrganización Panamericana de la Salud Washington D.C. Estados Unidos de América Organización Panamericana de la Salud, Washington D.C., Estados Unidos de América.
José Luis CastroOrganización Panamericana de la Salud Washington D.C. Estados Unidos de América Organización Panamericana de la Salud, Washington D.C., Estados Unidos de América.
World Health Organization Regional Office for the Americas · USDireccion General de Epidemiologia · MXInstituto de Salud Pública de Chile · CLUniversidad de Ciencias Médicas de la Habana · CU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Characterize and describe reports of suspected adverse reactions to a group of drugs used in Colombia, Costa Rica, Cuba, Chile, El Salvador, Mexico, and Peru to treat or prevent coronavirus disease (COVID-19) between 1 March and 31 August 2020. Methods: A list of the 13 drugs used to treat or prevent COVID-19 was prepared, based on official and unofficial sources. Drawing on the databases of the national pharmacovigilance programs of the participating countries, reports of suspected adverse reactions to these drugs were collected for the period from 1 March and 31 August 2020. Results: A total of 3 490 reports of suspected adverse reactions were received from the pharmacovigilance programs of Peru (n = 3 037), Cuba (n = 270), Colombia (n = 108), Chile (n = 72), and El Salvador (n = 3). The drugs with the highest number of reported adverse reactions were azithromycin, ivermectin, and hydroxychloroquine. Diarrhea was the most frequent event (15.0%). Of the total suspected adverse reactions, 11.9% were reported as serious. The most frequent was QT prolongation following use of hydroxychloroquine. Of these suspected serious adverse reactions, 54.5% occurred in people over 65 years of age. Conclusions: While it is not possible to establish a causal relationship from the evaluation of spontaneous reports, the present study confirms the presence of adverse reactions-some of them serious-involving drugs used to treat or prevent COVID-19.

Indexed as

anti-infective agentscoronavirus infectionsdrug evaluationdrug-related side effects and adverse reactionsdrug utilizationpatient safetyPharmacovigilance

Identifiers

PMID36196452
PMCPMC9524408
OpenAlexW4298109720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.